BIOA - BioAge Labs, Inc. News

BioAge Labs Doses First Participant Dosed In QUELL-CV

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-1

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

marketbeat.com

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Con

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesda

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgr

Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36

Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "th

This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday

Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes.

247wallst.com

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technolo

Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology s

BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40

BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascu

marketbeat.com

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, a

Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst cons

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among or

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical da

defenseworld.net

BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile

BioAge Labs (NASDAQ: BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 i

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 d

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts mai

zacks.com

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should K

The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the s

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potent

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in part

BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year

BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor tar

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "

Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

defenseworld.net

BioAge Labs (NASDAQ:BIOA) Stock Price Down 6% – Should You Sell?

BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report) shares dropped 6% during mid-day trading on Frida

This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

Needham Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $50

Needham analyst Joseph Stringer initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating

Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst cons

Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $52

Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the

defenseworld.net

BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report) was the target of a large growth in short interes

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Oppenheimer Initiates Coverage On Bioage Labs with Outperform Rating, Announces Price Target of $60

Oppenheimer analyst Jay Olson initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Outperform r

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62

Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the p

Piper Sandler Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $7

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Overw

Reported Earlier, BioAge Prices Upsized $115M Public Offering Of 5.9M Shares At $19.50 Per Share

BioAge intends to use the net proceeds from the proposed offering, together with its existing cash,

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “t

Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BioAge Labs Announces Up To $75M Common Stock Offering

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biophar

12 Health Care Stocks Moving In Tuesday's After-Market Session

BioAge Labs Expands BGE-102 Development Program Into Ophthalmology, With Initial Proof-Of-Concept St

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment bu

BioAge Labs Announces Additional Interim Data From Ongoing Phase 1 Clinical Trial Evaluating BGE-102

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; dem

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wedn

Morgan Stanley Upgrades Bioage Labs to Equal-Weight, Raises Price Target to $12

Morgan Stanley analyst Jeffrey Hung upgrades Bioage Labs (NASDAQ:BIOA) from Underweight to Equal-

Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar

BioAge Labs Data From BGE-102 Study Shows Well-Tolerance, Strong Target Engagement In Patients With

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company deve

Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst cons